Kevin Keown, MD
Family Medicine · Baxley, GANPI 1083606800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $906 and has fallen 93.6% since, to $58 in 2025.
Across 228 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$589
- Novo Nordisk$574
- AbbVie$394
- GSK$254
- Sanofi-aventis U.S. LLC$219
- Pfizer$215
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,749100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $589 |
| Novo Nordisk | 44 | $574 |
| AbbVie(2 entities) | 22 | $394 |
| GSK | 16 | $254 |
| Sanofi-aventis U.S. LLC | 11 | $219 |
| Pfizer | 14 | $215 |
| Amgen | 13 | $212 |
| Lilly USA, LLC | 13 | $203 |
| Boston Scientific | 5 | $122 |
| Novartis | 4 | $87 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Johnson & Johnson | 4 | $60 |
| Eisai Inc. | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Corium, LLC | 2 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Lundbeck LLC | 2 | $42 |
| Bausch Health US, LLC | 2 | $41 |
| Corcept Therapeutics | 2 | $41 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Exact Sciences | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Abbott | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Biogen | 1 | $12 |
| Merck | 1 | $12 |
| Indivior Inc. | 1 | $11 |
| Forte Bio-pharma LLC | 1 | $9 |
How this compares
$3,759 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 150 | $180,847 |
| MounjaroTirzepatide | 65 | $68,375 |
| JardianceEmpagliflozin | 37 | $56,777 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $42,982 |
| FarxigaDapagliflozin Propanediol | 19 | $25,872 |
| EliquisApixaban | 28 | $25,493 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $25,315 |
| LinzessLinaclotide | 26 | $22,209 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 446 | $14,349 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $9,934 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $7,412 |
| LantusInsulin Glargine,hum.Rec.Anlog | 35 | $6,121 |
| Gabapentin | 354 | $5,876 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,433 |
| Montelukast Sodium | 550 | $5,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $574 | $180,847150 claims |
| Lilly USA, LLCMounjaro | $203 | $68,37565 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $589 | $58,59993 claims |
| GSKTrelegy Ellipta | $254 | $42,98243 claims |
| PfizerEliquis | $215 | $25,49328 claims |
| AbbVieLinzess | $394 | $22,20926 claims |
| Sanofi-aventis U.S. LLCLantus | $219 | $6,12135 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $17 | $4,16748 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $24 | $2,14112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Baxley
- Jeffrey KingsleyColumbus$404K
- Debbie HaginsSavannah$279K
- Yolanda WadeTyrone$233K
- Julian HutchinsWarrenton$222K
- Nadine Halliburton-FosterCumming$219K
- Contessa MetcalfeAtlanta$157K
- Elmore AlexanderStone Mountain$155K
- Bantwal BaligaColumbus$115K
- Avril CampbellFort Benning$108K
- Mitzi RubinMarietta$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.